Chromogranin A (CgA) is a protein found in large dense-core vesicles of neuroendocrine cells and neurons and regulating secretion. A relevance to amyotrophic lateral sclerosis (ALS) was suggested as its overexpression accelerates disease onset in model systems and it interacts with mutant forms of SOD1. Recently, increased cerebrospinal fluid (CSF) CgA levels have been reported in ALS patients relative to controls. With the aim of confirming this finding, we measured CgA and phosphorylated neurofilament heavy chain (pNFH), an established ALS biomarker, in the CSF of 32 ALS patients and 32 disease controls. ALS patients had clearly increased pNFH levels (p < 0.0001), while CgA levels were only modestly lower relative to controls (p = 0.0265), with wide value overlap and consequently poor discriminative performance. CgA did not correlate with any disease parameters among ALS patients. Our findings suggest that CgA is not a promising clinical biomarker for ALS.

Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis / F. Verde, P. Steinacker, P. Oeckl, J.H. Weishaupt, A. Rosenbohm, V. Silani, A.C. Ludolph, M. Otto. - In: NEUROBIOLOGY OF AGING. - ISSN 0197-4580. - 67(2018), pp. 21-22. [10.1016/j.neurobiolaging.2018.02.017]

Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

F. Verde;V. Silani;
2018

Abstract

Chromogranin A (CgA) is a protein found in large dense-core vesicles of neuroendocrine cells and neurons and regulating secretion. A relevance to amyotrophic lateral sclerosis (ALS) was suggested as its overexpression accelerates disease onset in model systems and it interacts with mutant forms of SOD1. Recently, increased cerebrospinal fluid (CSF) CgA levels have been reported in ALS patients relative to controls. With the aim of confirming this finding, we measured CgA and phosphorylated neurofilament heavy chain (pNFH), an established ALS biomarker, in the CSF of 32 ALS patients and 32 disease controls. ALS patients had clearly increased pNFH levels (p < 0.0001), while CgA levels were only modestly lower relative to controls (p = 0.0265), with wide value overlap and consequently poor discriminative performance. CgA did not correlate with any disease parameters among ALS patients. Our findings suggest that CgA is not a promising clinical biomarker for ALS.
Amyotrophic lateral sclerosis (ALS); Cerebrospinal fluid (CSF); Chromogranin A (CgA); Phosphorylated neurofilament heavy chain (pNFH); Neuroscience (all); Aging; Neurology (clinical); Developmental Biology; Geriatrics and Gerontology
Settore MED/26 - Neurologia
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Verde F Neurobiol Aging 2018.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 182.75 kB
Formato Adobe PDF
182.75 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/571292
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact